This study is in progress, not accepting new patients
Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Peter Sayre
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Peter Sayre
Professor, Medicine, School of Medicine. Authored (or co-authored) 36 research publications. Research interests: Immune tolerance · hematologic malignancies · food allergy · transplantation tolerance · cellular therapies
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- MacroGenics
- ID
- NCT02152956
- Phase
- Phase 1/2 research study
- Study Type
- Interventional
- Last Updated